Do analysts rate REVB or MAAQ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, REVB or MAAQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revelation Biosciences N/A N/A -$8.91M -$39.48 N/A Mana Capital Acquisition N/A N/A N/A N/A N/A

Is REVB or MAAQ more profitable?

Mana Capital Acquisition's return on equity of 0.00% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -107.65% -87.98% Mana Capital Acquisition N/A N/A N/A

Do analysts recommend REVB or APLT?

Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is REVB or APLT more profitable?

Revelation Biosciences' return on equity of -107.65% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -107.65% -87.98% Applied Therapeutics N/A -340.84% -175.00%

Do analysts recommend NAII or REVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend REVB or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, REVB or QCLS?

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revelation Biosciences N/A N/A -$8.91M -$39.48 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is REVB or QCLS more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -107.65% -87.98% Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts recommend SNSE or REVB?

Sensei Biotherapeutics presently has a consensus target price of $48.00, indicating a potential upside of 240.18%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, SNSE or REVB?

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A Revelation Biosciences N/A N/A -$8.91M -$39.48 N/A

Is SNSE or REVB more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% Revelation Biosciences N/A -107.65% -87.98%

Revelation Biosciences (REVB) Competitors

$1.04 +0.05 (+4.89%)

As of 02:58 PM Eastern

Compare

REVB vs. MAAQ, APLT, NAII, QCLS, and SNSE

Should you buy Revelation Biosciences stock or one of its competitors? MarketBeat compares Revelation Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revelation Biosciences include Mana Capital Acquisition (MAAQ), Applied Therapeutics (APLT), Natural Alternatives International (NAII), Mymd Pharmaceuticals (QCLS), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry.

How does Revelation Biosciences compare to Mana Capital Acquisition?

Revelation Biosciences (NASDAQ:REVB) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Mana Capital Acquisition's return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-107.65%	-87.98%
Mana Capital Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Revelation Biosciences had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for Mana Capital Acquisition. Revelation Biosciences' average media sentiment score of 1.89 beat Mana Capital Acquisition's score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Revelation Biosciences	Very Positive
Mana Capital Acquisition	Neutral

Summary

Revelation Biosciences beats Mana Capital Acquisition on 4 of the 7 factors compared between the two stocks.

How does Revelation Biosciences compare to Applied Therapeutics?

Revelation Biosciences (NASDAQ:REVB) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Revelation Biosciences has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Revelation Biosciences has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Revelation Biosciences' return on equity of -107.65% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-107.65%	-87.98%
Applied Therapeutics	N/A	-340.84%	-175.00%

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Revelation Biosciences had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for Applied Therapeutics. Revelation Biosciences' average media sentiment score of 1.89 beat Applied Therapeutics' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Revelation Biosciences	Very Positive
Applied Therapeutics	Neutral

Summary

Revelation Biosciences beats Applied Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Revelation Biosciences has lower revenue, but higher earnings than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.13	-$13.57M	-$2.39	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A

Revelation Biosciences has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Revelation Biosciences	N/A	-107.65%	-87.98%

32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 20.8% of Natural Alternatives International shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Natural Alternatives International has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market.

In the previous week, Natural Alternatives International had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 2 mentions for Natural Alternatives International and 1 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 1.89 beat Natural Alternatives International's score of 0.45 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Natural Alternatives International	Neutral
Revelation Biosciences	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Natural Alternatives International beats Revelation Biosciences on 8 of the 12 factors compared between the two stocks.

How does Revelation Biosciences compare to Mymd Pharmaceuticals?

Revelation Biosciences (NASDAQ:REVB) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals' return on equity of -76.40% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-107.65%	-87.98%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Revelation Biosciences has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market.

In the previous week, Revelation Biosciences and Revelation Biosciences both had 1 articles in the media. Revelation Biosciences' average media sentiment score of 1.89 beat Mymd Pharmaceuticals' score of 1.87 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Revelation Biosciences	Very Positive
Mymd Pharmaceuticals	Very Positive

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

Summary

Revelation Biosciences beats Mymd Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Revelation Biosciences compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:SNSE) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sensei Biotherapeutics' return on equity of -83.59% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Revelation Biosciences	N/A	-107.65%	-87.98%

Sensei Biotherapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Revelation Biosciences. MarketBeat recorded 3 mentions for Sensei Biotherapeutics and 1 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 1.89 beat Sensei Biotherapeutics' score of 1.43 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Sensei Biotherapeutics	Positive
Revelation Biosciences	Very Positive

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A

Sensei Biotherapeutics presently has a consensus target price of $48.00, indicating a potential upside of 240.18%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Revelation Biosciences beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REVB vs. The Competition

Export

Metric	Revelation Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.09M	$3.38B	$6.48B	$12.36B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.03	20.03	23.95	24.60
Price / Sales	N/A	320.04	536.37	171.61
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.82	8.01	10.44	6.77
Net Income	-$8.91M	$23.89M	$3.56B	$337.32M
7 Day Performance	3.47%	2.12%	0.83%	2.06%
1 Month Performance	6.71%	0.09%	1.78%	3.93%
1 Year Performance	-89.03%	44.59%	25.59%	32.29%

Revelation Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REVB Revelation Biosciences	1.4128 of 5 stars	$1.05 +4.9%	N/A	-89.5%	$4.09M	N/A	N/A	10	Positive News Gap Up
MAAQ Mana Capital Acquisition	N/A	$1.96 -7.1%	N/A	-51.7%	$15.93M	N/A	N/A	1
APLT Applied Therapeutics	1.4295 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
NAII Natural Alternatives International	0.6043 of 5 stars	$2.51 flat	N/A	-28.9%	$15.76M	$129.86M	N/A	290	Short Interest Increase
QCLS Mymd Pharmaceuticals	1.7658 of 5 stars	$3.71 -2.1%	N/A	N/A	$15.47M	N/A	N/A	6	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REVB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revelation Biosciences (REVB) Competitors

REVB vs. MAAQ, APLT, NAII, QCLS, and SNSE

How does Revelation Biosciences compare to Mana Capital Acquisition?

Summary

How does Revelation Biosciences compare to Applied Therapeutics?

Summary

How does Revelation Biosciences compare to Natural Alternatives International?

Summary

How does Revelation Biosciences compare to Mymd Pharmaceuticals?

Summary

How does Revelation Biosciences compare to Sensei Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB vs. The Competition

Revelation Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revelation Biosciences (REVB) Competitors

REVB vs. MAAQ, APLT, NAII, QCLS, and SNSE

How does Revelation Biosciences compare to Mana Capital Acquisition?

Which has better earnings & valuation, REVB or MAAQ?

Is REVB or MAAQ more profitable?

Do analysts rate REVB or MAAQ?

Do institutionals & insiders have more ownership in REVB or MAAQ?

Does the media refer more to REVB or MAAQ?

Summary

How does Revelation Biosciences compare to Applied Therapeutics?

Which has higher earnings & valuation, REVB or APLT?

Which has more risk and volatility, REVB or APLT?

Do analysts recommend REVB or APLT?

Is REVB or APLT more profitable?

Do institutionals & insiders hold more shares of REVB or APLT?

Does the media favor REVB or APLT?

Summary

How does Revelation Biosciences compare to Natural Alternatives International?

Which has better earnings and valuation, NAII or REVB?

Is NAII or REVB more profitable?

Do insiders & institutionals believe in NAII or REVB?

Which has more volatility and risk, NAII or REVB?

Does the media prefer NAII or REVB?

Do analysts recommend NAII or REVB?

Summary

How does Revelation Biosciences compare to Mymd Pharmaceuticals?

Do analysts recommend REVB or QCLS?

Is REVB or QCLS more profitable?

Which has more volatility & risk, REVB or QCLS?

Does the media favor REVB or QCLS?

Do insiders and institutionals hold more shares of REVB or QCLS?

Which has stronger earnings and valuation, REVB or QCLS?

Summary

How does Revelation Biosciences compare to Sensei Biotherapeutics?

Do institutionals & insiders believe in SNSE or REVB?

Is SNSE or REVB more profitable?

Which has more risk and volatility, SNSE or REVB?

Does the media prefer SNSE or REVB?

Which has preferable earnings & valuation, SNSE or REVB?

Do analysts recommend SNSE or REVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB vs. The Competition

Revelation Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools